An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen

TOURMALINE MM-6

Overview

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have multiple myeloma (MM). This study will look at the effectiveness and safety in participants who take ixazomib in addition to lenalidomide and dexamethasone.

SparkCures ID 925
Trial Phase Phase 4
Enrollment 160 Patients
Treatments
Trial Sponsors
  • Takeda Oncology
NCT Identifier

NCT03173092

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Must have a diagnosis of a MM using current IMWG diagnostic criteria and have received 1 prior line of therapy.
    • Participants must have completed 3 cycles of a bortezomib-based induction regimen (as defined by current NCCN guidelines) and have no evidence of disease progression as defined by IMWG criteria.
    • Participants with light chain and free light chain (FLC) only may be enrolled if they meet all the criteria for a diagnosis of MM.
    • Participants must be considered by their physician eligible to receiving the IRD regimen.
  2. Must be transplant ineligible as determined by their physician, or if transplant eligible, not expect to undergo transplant for at least 24 months after study enrollment.

    o Stem cell harvest and mobilization regimen is acceptable if clinically indicated, but must first be confirmed by the Takeda Medical Monitor.

  3. Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2 at time of enrollment.
  4. Female participants who:
    • Are postmenopausal for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence [example, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
  5. Male participants, even if surgically sterilized (that is, status post-vasectomy), must agree to one of the following:
    • Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence (example, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).

Exclusion Criteria:

  1. Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial. Non-interventional trials (that is, observational trials) are permitted at any time point.
  2. Failure to have fully recovered (that is, less than or equal to [<=] Grade 1 toxicity) from the reversible effects of prior chemotherapy.
  3. Major surgery within 14 days before enrollment.
  4. Radiotherapy within 14 days before enrollment (if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib).
  5. Central nervous system involvement.
  6. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
  7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
  8. Systemic treatment, within 14 days before the first dose of ixazomib, with strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.
  9. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus positive.
  10. Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  11. Has greater than or equal to (>=) Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during the screening period.
  12. Have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not.
  13. PD on first-line therapy.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Arizona Oncology Associates PC Tucson - Rudasill - Medical Oncology

Tucson, AZ

Pacific Cancer Medical Center Inc.

Anaheim, CA

Compassionate Cancer Care

Fountain Valley, CA

Innovative Clinical Research Institute

Whittier, CA

Woodlands Medical Specialists

Pensacola, FL

Grady Memorial Hospital

Atlanta, GA

Investigative Clinical Research Of Indiana, LLC

Indianapolis, IN

Ochsner Medical Center

Jefferson, LA

Saint Agnes Hospital Saint Agnes Healthcare

Baltimore, MD

Central Care Cancer Center

Bolivar, MO

Kansas City VA Medical Center

Kansas City, MO

San Juan Oncology Associates

Farmington, NM

Comprehensive Cancer Centers of Nevada (Henderson)

Henderson, NV

TriHealth Cancer Institute (Westside)

White Oak, OH

Willamette Valley Cancer Institute and Research Center RiverBend Pavilion in Springfield

Springfield, OR

Avera Cancer Institute

Sioux Falls, SD

Texas Oncology (Presbyterian Hospital)

Dallas, TX

Cancer Center Associates

Mesquite, TX

Texas Oncology San Antonio Northeast

San Antonio, TX

Millennium Physicians

Shenandoah, TX

Texas Oncology

Tyler, TX

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Queens Medical Associates, PC

Fresh Meadows, NY

Clinical Research Alliance

Lake Success, NY

Cleveland VA Medical Center

Cleveland, OH

Arizona
Arizona Oncology Associates PC Tucson - Rudasill - Medical Oncology

Tucson, AZ

California
Pacific Cancer Medical Center Inc.

Anaheim, CA

Compassionate Cancer Care

Fountain Valley, CA

Innovative Clinical Research Institute

Whittier, CA

Colorado
Florida
Woodlands Medical Specialists

Pensacola, FL

Georgia
Grady Memorial Hospital

Atlanta, GA

Indiana
Investigative Clinical Research Of Indiana, LLC

Indianapolis, IN

Louisiana
Ochsner Medical Center

Jefferson, LA

Maryland
Saint Agnes Hospital Saint Agnes Healthcare

Baltimore, MD

Missouri
Central Care Cancer Center

Bolivar, MO

Kansas City VA Medical Center

Kansas City, MO

Nevada
Comprehensive Cancer Centers of Nevada (Henderson)

Henderson, NV

New Mexico
San Juan Oncology Associates

Farmington, NM

New York
Queens Medical Associates, PC

Fresh Meadows, NY

Clinical Research Alliance

Lake Success, NY

Ohio
Cleveland VA Medical Center

Cleveland, OH

TriHealth Cancer Institute (Westside)

White Oak, OH

Oregon
Willamette Valley Cancer Institute and Research Center RiverBend Pavilion in Springfield

Springfield, OR

Pennsylvania
South Dakota
Avera Cancer Institute

Sioux Falls, SD

Texas
Texas Oncology (Presbyterian Hospital)

Dallas, TX

Cancer Center Associates

Mesquite, TX

Texas Oncology San Antonio Northeast

San Antonio, TX

Millennium Physicians

Shenandoah, TX

Texas Oncology

Tyler, TX

Resources

There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message